153 related articles for article (PubMed ID: 31180526)
1. USP39 promotes ovarian cancer malignant phenotypes and carboplatin chemoresistance.
Wang L; Chen T; Li X; Yan W; Lou Y; Liu Z; Chen H; Cui Z
Int J Oncol; 2019 Jul; 55(1):277-288. PubMed ID: 31180526
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-specific peptidase 39 regulates the process of proliferation and migration of human ovarian cancer via p53/p21 pathway and EMT.
Yan C; Yuan J; Xu J; Zhang G; Li X; Zhang B; Hu T; Huang X; Mao Y; Song G
Med Oncol; 2019 Oct; 36(11):95. PubMed ID: 31637536
[TBL] [Abstract][Full Text] [Related]
3. USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway.
Cai J; Liu T; Huang P; Yan W; Guo C; Xiong L; Liu A
Biochem Biophys Res Commun; 2017 Apr; 486(1):184-190. PubMed ID: 28286270
[TBL] [Abstract][Full Text] [Related]
4. USP48 Sustains Chemoresistance and Metastasis in Ovarian Cancer.
Lei X; Li X; Chen H; Liu Z
Curr Cancer Drug Targets; 2020; 20(9):689-699. PubMed ID: 32359336
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of ubiquitin‑specific peptidase 39 inhibits the malignant progression of human renal cell carcinoma.
Xu Y; Zhu MR; Zhang JY; Si GM; Lv JJ
Mol Med Rep; 2018 Mar; 17(3):4729-4735. PubMed ID: 29328477
[TBL] [Abstract][Full Text] [Related]
6. USP39 promotes the growth of human hepatocellular carcinoma in vitro and in vivo.
Yuan X; Sun X; Shi X; Jiang C; Yu D; Zhang W; Guan W; Zhou J; Wu Y; Qiu Y; Ding Y
Oncol Rep; 2015 Aug; 34(2):823-32. PubMed ID: 26081192
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of USP39 induces cell cycle arrest and apoptosis in melanoma.
Zhao Y; Zhang B; Lei Y; Sun J; Zhang Y; Yang S; Zhang X
Tumour Biol; 2016 Oct; 37(10):13167-13176. PubMed ID: 27456357
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation.
Huang Y; Pan XW; Li L; Chen L; Liu X; Lu JL; Zhu XM; Huang H; Yang QW; Ye JQ; Gan SS; Wang LH; Hong Y; Xu DF; Cui XG
Oncotarget; 2016 Apr; 7(16):22016-30. PubMed ID: 26959883
[TBL] [Abstract][Full Text] [Related]
9. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-specific protease 39 is overexpressed in human lung cancer and promotes tumor cell proliferation in vitro.
Lin Z; Xiong L; Lin Q
Mol Cell Biochem; 2016 Nov; 422(1-2):97-107. PubMed ID: 27629785
[TBL] [Abstract][Full Text] [Related]
11. USP39 mediates p21-dependent proliferation and neoplasia of colon cancer cells by regulating the p53/p21/CDC2/cyclin B1 axis.
Yuan J; Li X; Zhang G; Cheng W; Wang W; Lei Y; Ma Q; Song G
Mol Carcinog; 2021 Apr; 60(4):265-278. PubMed ID: 33634905
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
[TBL] [Abstract][Full Text] [Related]
13. S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin.
Wang L; Yan W; Li X; Liu Z; Tian T; Chen T; Zou L; Cui Z
J Ovarian Res; 2019 Nov; 12(1):113. PubMed ID: 31739800
[TBL] [Abstract][Full Text] [Related]
14. Knocking down USP39 Inhibits the Growth and Metastasis of Non-Small-Cell Lung Cancer Cells through Activating the p53 Pathway.
Yuan J; Zhang G; Li X; Ma Q; Cheng W; Wang W; Zhang B; Hu T; Song G
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255748
[TBL] [Abstract][Full Text] [Related]
15. Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2.
Wang S; Wang Z; Li J; Qin J; Song J; Li Y; Zhao L; Zhang X; Guo H; Shao C; Kong B; Liu Z
Cell Death Dis; 2021 Mar; 12(4):294. PubMed ID: 33731694
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of ubiquitin-specific peptidase 39 inhibited the growth of osteosarcoma cells and induced apoptosis in vitro.
Gan Z; Han K; Lin S; Hu H; Shen Z; Min D
Biol Res; 2017 Apr; 50(1):15. PubMed ID: 28403900
[TBL] [Abstract][Full Text] [Related]
17. USP39 regulates the cell cycle, survival, and growth of human leukemia cells.
Liu C; Yao X; Li M; Xi Y; Zhao L
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898977
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
20. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
